Purpose: This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy. Methods: Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25-75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan-Meier curves, as appropriate. Results: Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245). Conclusions: Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.

[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia / Rinzivillo, M; Prosperi, D; Mazzuca, F; Magi, L; Iannicelli, E; Pilozzi, E; Franchi, G; Silveri, Gg; Laghi, A; Annibale, B; Signore, A; Panzuto, F. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 31:supplemento 4(2020), pp. S782-S782. ((Intervento presentato al convegno ESMO Virtual Congress tenutosi a ELECTR NETWORK [10.1016/j.annonc.2020.08.1398].

[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia

Rinzivillo, M;Prosperi, D;Mazzuca, F;Magi, L;Iannicelli, E;Pilozzi, E;Franchi, G;Laghi, A;Annibale, B;Signore, A;Panzuto, F
2020

Abstract

Purpose: This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy. Methods: Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25-75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan-Meier curves, as appropriate. Results: Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245). Conclusions: Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.
ESMO Virtual Congress
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia / Rinzivillo, M; Prosperi, D; Mazzuca, F; Magi, L; Iannicelli, E; Pilozzi, E; Franchi, G; Silveri, Gg; Laghi, A; Annibale, B; Signore, A; Panzuto, F. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 31:supplemento 4(2020), pp. S782-S782. ((Intervento presentato al convegno ESMO Virtual Congress tenutosi a ELECTR NETWORK [10.1016/j.annonc.2020.08.1398].
File allegati a questo prodotto
File Dimensione Formato  
Rinzivillo_[18F]FDG-PETCT_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 707.35 kB
Formato Adobe PDF
707.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1506532
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact